Upgrade to SI Premium - Free Trial

Mizuho Reiterates Outperform Rating on Relmada Therapeutics Inc (RLMD): pullback 'a buying opprotunity'

March 13, 2026 2:49 PM
Mizuho analyst Uy Ear reiterated an Outperform rating and $10.00 price target on Relmada Therapeutics Inc (NASDAQ: RLMD)The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments